SOURCE: Neuroscience & Biobehavioral Reviews. 139:104743, 2022 Aug.
Welcome to TMS Solutions' resource portal, Solute, where you will find the latest informative articles about mental health, neuromodulation techniques, and TMS.
Relevant Posts
Aug 17, 2022 4:08:00 PM
Brain Stimulation and Other Biological Non-Pharmacological Interventions in Mental Disorders: An Umbrella Review [Review]
Jul 10, 2022 11:56:00 AM
Cerebellar Continuous Theta Burst Stimulation for Aphasia Rehabilitation: Study Protocol for a Randomized Controlled Trial
SOURCE: Frontiers in Aging Neuroscience. 14 (no pagination), 2022. Article Number: 909733.
Read MoreJun 23, 2022 11:15:00 AM
Glutamatergic System in Depression and Its Role in Neuromodulatory Techniques Optimization
Apr 3, 2022 3:46:00 PM
rTMS Combined With CBT as a Next Step in Antidepressant Non-Responders: A Study Protocol for a Randomized Comparison With Current Antidepressant Treatment Approaches
Dec 21, 2021 11:27:00 AM
Neuromodulatory Treatments for Psychiatric Disease: A Comprehensive Survey of the Clinical Trial Landscape [Review]
Source: Brain Stimulation. 14(5):1393-1403, 2021 Sep-Oct.
Authors: Elias GJB; Boutet A; Parmar R; Wong EHY; Germann J; Loh A; Paff M; Pancholi A; Gwun D; Chow CT; Gouveia FV; Harmsen IE; Beyn ME; Santarnecchi E; Fasano A; Blumberger DM; Kennedy SH; Lozano AM; Bhat V
Abstract
BACKGROUND: Numerous neuromodulatory therapies are currently under investigation or in clinical use for the treatment of psychiatric conditions.
OBJECTIVE/HYPOTHESIS: We sought to catalogue past and present human research studies on psychiatric neuromodulation and identify relevant trends in this field.
METHODS: ClinicalTrials.gov (https://www.clinicaltrials.gov/) and the International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/) were queried in March 2020 for trials assessing the outcome of neuromodulation for psychiatric disorders. Relevant trials were categorized by variables such as neuromodulation
modality, country, brain target, publication status, design, and funding source.
RESULTS: From 72,086 initial search results, 1252 unique trials were identified. The number of trials registered annually has consistently increased. Half of all trials were active and a quarter have translated to publications. The largest proportion of trials involved depression (45%), schizophrenia (18%), and substance use disorders (14%). Trials spanned 37 countries; China, the second largest contributor (13%) after the United States (28%), has increased its output substantially in recent years. Over
75% of trials involved non-convulsive non-invasive modalities (e.g., transcranial magnetic stimulation), while convulsive (e.g., electroconvulsive therapy) and invasive modalities (e.g., deep brain stimulation) were less represented. 72% of trials featured approved or cleared interventions. Characteristic inter-modality differences were observed with respect to enrollment size, trial design/phase, and funding. Dorsolateral prefrontal cortex accounted for over half of focal neuromodulation trial targets. The proportion of trials examining biological correlates of neuromodulation has increased.
CONCLUSION(S): These results provide a comprehensive overview of the state of psychiatric neuromodulation research, revealing the growing scope and internationalism of this field.
